Gyre Therapeutics
GYRE
75 hedge funds and large institutions have $95.2M invested in Gyre Therapeutics in 2018 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 17 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 8
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
34% more funds holding
Funds holding: 56 → 75 (+19)
10% less call options, than puts
Call options by funds: $3.75M | Put options by funds: $4.16M
1.17% less ownership
Funds ownership: 10.27% → 9.1% (-1.2%)
60% less capital invested
Capital invested by funds: $236M → $95.2M (-$141M)
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14M |
| 2 |
BlackRock
New York
|
+$13.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$12.9M |
| 4 |
NC
Nexthera Capital
New York
|
+$5.81M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$5.75M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$26.4M |
| 2 |
DM
Deerfield Management
New York
|
-$21.4M |
| 3 |
SCM
Sio Capital Management
New York
|
-$15.9M |
| 4 |
VMI
VHCP Management II
New York
|
-$14.3M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.3M |
GYRE Hedge Fund Activity: Q2 2018 in Review
75 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2018, worth a combined $95.2M — down 60% from $236M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new GYRE positions and 17 closed out — a net gain of 20 holders — while 24 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $14M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $26.4M sold.
- 75 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2018, up from 56 in Q1 2018.
- Funds reported $95.2M of Gyre Therapeutics stock for Q2 2018, down 60% quarter-over-quarter.
- 37 funds opened new Gyre Therapeutics positions in Q2 2018 and 17 closed out, a net change of +20 holders.
- The largest Gyre Therapeutics buyer in Q2 2018 was Point72 Asset Management, an estimated $14M added.
- The largest Gyre Therapeutics seller in Q2 2018 was Avoro Capital Advisors, an estimated $26.4M sold.
Based on aggregated 13F filings for Q2 2018.